POS1077 LARGE JOINT INVOLVEMENT AND SUBSTANTIAL DISEASE BURDEN IN PATIENTS WITH OLIGOARTICULAR AND POLYARTICULAR PSORIATIC ARTHRITIS IN THE MULTINATIONAL UPLIFT SURVEY
Authors: W. Tillett, A. Ogdie, P. Richette, A. B. Gottlieb, S. Jardon, S. Richter, A. Flower, J. Merola
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients (pts) with oligoarticular psoriatic arthritis (PsA) report quality-of-life impairment similar to polyarticular PsA pts despite less joint involvement. In the 2020 Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey, we evaluated other aspects of disease burden in pts with oligoarticular (≤4 joints) and polyarticular (&gt;4 joints) PsA. Objectives To explore joint involvement distribution and relative disease burden in pts with self-reported healthcare provider (HCP)–diagnosed PsA who self-identified with oligoarticular vs polyarticular joint involvement. Methods UPLIFT was a multinational Web-based survey in adults who reported an HCP diagnosis of PsA and/or psoriasis. This analysis evaluated demographics, disease characteristics, joint distribution, and quality-of-life measures in pts with PsA with or without psoriasis with self-identified oligoarticular vs polyarticular joint involvement. Small joint classification includes foot/toes, hands/fingers, and thumbs; intermediate joints includes wrists, elbows, and ankles; and large joints includes shoulders, hips, and knees. Results Of the 1256 pts with PsA completing the survey, 44% had oligoarticular PsA and 56% polyarticular PsA. The polyarticular PsA group had higher mean age, fewer males, and more pts with body mass index ≥25 kg/m 2 (Table 1). Prevalence of depression, hypertension, and diabetes was generally similar between groups (Table 1). In pts with oligoarticular and polyarticular PsA, respectively, involvement of large joints was most prevalent (63%, 91%), followed by intermediate (46%, 87%) and small (20%, 76%) joints. Axial involvement was less prevalent in pts with oligoarticular (30%) vs polyarticular (67%) PsA. Common areas of joint involvement were the knees, elbows, and shoulders for oligoarticular PsA pts and the knees, hands, and elbows for polyarticular PsA pts (Figure 1). Involvement in the hands, wrists, thumbs, feet, and ankles was proportionately greater in polyarticular pts vs oligoarticular pts. Dactylitis, enthesitis, and nail disease, respectively, were each present in approximately one third of oligoarticular PsA pts and more than half of polyarticular PsA pts. Mean Patient Assessment of PsA Severity, Health Assessment Questionnaire (HAQ)-8, and Psoriatic Arthritis Impact of Disease 12-item (PSAID-12) scores indicated similar disease burden between the two groups (Table 1). In both groups, &gt;70% reported an unacceptable PsA symptom state (PSAID &gt;4), and &gt;60% had Patient Health Questionnaire 2-item (PHQ-2) score ≥3, consistent with positive screening for depression (Table 1). Table 1. Demographics and Patient Characteristics Oligoarticular PsA (n=550 ) Polyarticular PsA (n=706 ) Age, mean (SD), y 39.5 (15.23) 45.6 (14.89) Male sex, n (%) 327 (60) 347 (49) Body mass index ≥25 kg/m 2 (overweight/obese), n (%) 164 (30) 292 (41) PsA duration, mean (SD), y 11.1 (10.44) 13.8 (11.40) PsA treatment use, n (%)* Prior oral prescription 231 (44) 217 (31) Prior injectable/intravenous 177 (34) 169 (24) Current oral prescription 185 (35) 364 (53) Current injectable/ intravenous 154 (29) 246 (36) Comorbidities, n (%) Hypertension 230 (42) 302 (43) Depression 214 (39) 291 (41) Diabetes 201 (37) 236 (33) Skin or non-skin cancer 200 (36) 168 (24) Heart disease 149 (27) 123 (17) Inflammatory bowel disease 156 (28) 142 (20) Liver disease 149 (27) 98 (14) Patient Assessment of PsA Severity, mean, (SD) 5.0 (2.92) 5.7 (2.53) HAQ-8, mean, (SD) 0.9 (0.65) 0.8 (0.64) PSAID-12, mean, (SD) 5.3 (2.54) 5.6 (2.42) PSAID &gt;4, n (%) 389 (71) 533 (76) PHQ-2 ≥3, n (%) 383 (70) 452 (64) *n=525 with oligoarticular PsA; n=691 with polyarticular PsA. Conclusion In the UPLIFT survey, almost half of pts with PsA self-identified with oligoarticular PsA. Both oligoarticular and polyarticular PsA groups experienced similar levels of disease burden, including a high prevalence of an unacceptable PsA symptom state and a PHQ-2 score ≥3, indicative of a positive screen for depression. Acknowledgements The authors gratefully acknowledge Hsiuan Lin Wu for data analysis. This study was funded by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Kristin Carlin, BSPharm, MBA, of Peloton Advantage, LLC, an OPEN Health company, and Cathryn M. Carter, MS, employee of and stockholder in Amgen Inc. Disclosure of Interests William Tillett Speakers bureau: AbbVie, Amgen Inc., Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen Inc., Celgene, Eli Lilly, Merck Sharp &amp; Dohme, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Celgene, Eli Lilly, and Janssen, Alexis Ogdie Consultant of: AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, CorEvitas’ Psoriatic Arthritis/Spondyloarthritis Registry (formerly Corrona), Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen Inc., Novartis, and Pfizer, Pascal Richette Speakers bureau: AbbVie, Amgen Inc., Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB, Alice B Gottlieb Consultant of: Anaptyps Bio, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, LEO Pharma, Eli Lilly, Novartis, Sun, UCB, and Xbiotech, Grant/research support from: Boehringer Ingelheim, Janssen, Novartis, Sun, UCB, and Xbiotech, Shauna Jardon Shareholder of: Stock ownership in Amgen Inc, Employee of: Employee of Amgen Inc, Sven Richter Shareholder of: Stock ownership in Amgen at time of study, Employee of: Employment by Amgen at time of study, Andrea Flower Employee of: Employment by ProUnlimited, under contract for Amgen Inc., Joseph Merola Consultant of: AbbVie, Arena, Avotres, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, EMD, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Serono, Sun, and UCB